JP Morgan 2025: Novartis streamlines its portfolio to drive future growth
Positioning itself as a pure-play innovative medicines company, Novartis is bullish about the growth towards 2030 by placing an emphasis …
Post
-
-
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for …
-
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for …
-
Clinical research survey results: The key pressures for SMEs and business outlook
The pharma sector is at a crossroads, with major challenges for small and medium-sized businesses driving clinical research. However, there …
-
J&J to leverage Intra-Cellular Therapies’ neurology portfolio
On 13 January 2024, Johnson & Johnson (J&J) announced the acquisition of Intra-Cellular Therapies, a biopharmaceutical company specialising in developing …
-
Pharma to raise prices on more than 250 drugs in the US from January 2025
This January, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US, …
-
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi …
-
Normunity raises $75m to advance solid tumour targeting T-cell engagers
US-based Normunity has raised $75m in a Series B funding round to support the clinical development of its lead programme, …
-
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting at …
-
Enhancing patient engagement and outcomes in the NHS
Medication non-adherence is an enduring issue in the UK healthcare system, costing the NHS a staggering £930 million annually.[i] Despite …
-
Pharmaceutical Technology Excellence Awards 2024: Syngene
Syngene International is a leading integrated contract research, development, and manufacturing organization (CRDMO). The company was honored with three awards …
-
Pharmaceutical Technology Excellence Awards 2024: IFF Pharma Solutions
IFF Pharma Solutions has been recognized for its marketing strategies and leadership in controlled release technologies, earning the Marketing Award …
-
Pharmaceutical Technology Excellence Awards 2024: Image Analysis Group
IImage Analysis Group (IAG) has won an award in the Innovation category in the 2024 Pharmaceutical Technology Excellence Awards for …
-
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away …
-
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues …
